Edita Navratilova Selected Research

kappa Opioid Receptors (kappa Opioid Receptor)

4/2022	Chronic pain recruits hypothalamic dynorphin/kappa opioid receptor signalling to promote wakefulness and vigilance.
1/2022	Kappa Opioid Receptor Blockade in the Amygdala Mitigates Pain Like-Behaviors by Inhibiting Corticotropin Releasing Factor Neurons in a Rat Model of Functional Pain.
1/2022	Dysregulation of serum prolactin links the hypothalamus with female nociceptors to promote migraine.
1/2021	Kappa opioid receptor activation in the amygdala disinhibits CRF neurons to generate pain-like behaviors.
1/2021	A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain.
4/2019	Kappa opioid signaling in the central nucleus of the amygdala promotes disinhibition and aversiveness of chronic neuropathic pain.
5/2018	Lateralized kappa opioid receptor signaling from the amygdala central nucleus promotes stress-induced functional pain.
7/2017	Kappa opioid receptor antagonists: A possible new class of therapeutics for migraine prevention.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Edita Navratilova Research Topics

Disease

37	Pain (Aches) 10/2022 - 12/2003
25	Hyperalgesia 10/2022 - 07/2017
14	Neuralgia (Stump Neuralgia) 04/2022 - 08/2010
12	Chronic Pain 04/2022 - 11/2015
11	Migraine Disorders (Migraine) 01/2022 - 07/2017
6	Hypersensitivity (Allergy) 01/2022 - 06/2012
5	Secondary Headache Disorders 01/2022 - 01/2019
3	Post-Traumatic Headache 10/2022 - 12/2019
3	Brain Concussion (Cerebral Concussion) 10/2022 - 12/2019
2	Headache (Headaches) 10/2022 - 12/2019
2	Acute Pain 04/2019 - 12/2018
2	Neoplasms (Cancer) 01/2018 - 10/2015
1	Nervous System Diseases (Neurological Disorders) 01/2022
1	Migraine without Aura (Common Migraine) 01/2022
1	Memory Disorders (Memory Loss) 11/2021
1	Parkinson Disease (Parkinson's Disease) 10/2020
1	Wounds and Injuries (Trauma) 01/2020
1	Osteosarcoma (Osteogenic Sarcoma) 01/2018
1	Inflammation (Inflammations) 12/2016
1	Cancer Pain 10/2015

Drug/Important Bio-Agent (IBA)

17	Opioid Analgesics (Opioids)IBA 07/2021 - 12/2003
9	Dopamine (Intropin)FDA LinkGeneric 01/2022 - 12/2012
8	kappa Opioid Receptors (kappa Opioid Receptor)IBA 04/2022 - 07/2017
8	Analgesics (Analgesic Drugs)IBA 11/2021 - 06/2007
8	Morphine (MS Contin)FDA LinkGeneric 07/2021 - 04/2008
6	norbinaltorphimineIBA 04/2022 - 07/2017
6	salicylhydroxamic acid (SHAM)IBA 01/2022 - 10/2015
6	Sumatriptan (Imigran)FDA LinkGeneric 01/2022 - 07/2017
6	6-chloro-2-(1-piperazinyl)pyrazine (CPP)IBA 01/2020 - 08/2014
5	Calcitonin Gene-Related PeptideIBA 01/2021 - 04/2008
4	Dynorphins (Dynorphin)IBA 04/2022 - 05/2018
4	ProlactinIBA 01/2022 - 01/2020
4	Gabapentin (Neurontin)FDA LinkGeneric 11/2021 - 08/2014
4	Pharmaceutical PreparationsIBA 01/2020 - 04/2013
3	(1R,5S)- 4- methyl- 1- propan- 2- ylbicyclo(3.1.0)hex- 3- en- 2- oneIBA 01/2022 - 12/2020
3	Prolactin Receptors (Prolactin Receptor)IBA 01/2022 - 01/2020
3	Monoclonal AntibodiesIBA 01/2021 - 12/2019
3	Peptides (Polypeptides)IBA 12/2020 - 06/2007
3	mu Opioid Receptors (mu Opioid Receptor)IBA 01/2020 - 06/2007
3	Opioid Receptors (Opioid Receptor)IBA 01/2020 - 10/2015
2	LigandsIBA 04/2022 - 06/2007
2	Protein Isoforms (Isoforms)IBA 01/2022 - 01/2020
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 08/2014
2	Calcitonin Gene-Related Peptide Receptor AntagonistsIBA 01/2021 - 01/2020
2	fremanezumabIBA 01/2021 - 12/2020
2	NeuropeptidesIBA 01/2020 - 01/2019
2	Capsaicin (Zostrix)FDA Link 01/2019 - 05/2018
2	Substance PIBA 01/2019 - 08/2010
2	Neurotransmitter Agents (Neurotransmitter)IBA 04/2008 - 12/2003
1	Type A Botulinum Toxins (Botox)FDA Link 10/2022
1	Proteins (Proteins, Gene)FDA Link 01/2022
1	Cabergoline FDA LinkGeneric 01/2022
1	Corticotropin-Releasing HormoneIBA 01/2022
1	AntibodiesIBA 01/2022
1	Dopamine Agonists (Dopamine Agonist)IBA 01/2022
1	QuinpiroleIBA 01/2022
1	Lidocaine (Xylocaine)FDA LinkGeneric 11/2021
1	Levodopa (L Dopa)FDA LinkGeneric 11/2021
1	Duloxetine Hydrochloride (Cymbalta)FDA Link 11/2021
1	Naloxone (Narcan)FDA LinkGeneric 07/2021
1	olcegepantIBA 01/2021
1	Propranolol (Inderal)FDA LinkGeneric 01/2021
1	Calcitonin Gene-Related Peptide Receptors (Calcitonin-Gene Related Peptide Receptor)IBA 01/2021
1	AmidesIBA 12/2020
1	AnkyrinsIBA 12/2020
1	seryl- leucyl- isoleucyl- glycyl- arginyl- leucineIBA 12/2020
1	Calcitonin (Calcitonin, Eel)FDA LinkGeneric 12/2020
1	PAR-2 ReceptorIBA 12/2020
1	Tryptases (Tryptase)IBA 12/2020
1	Peptide Hydrolases (Proteases)FDA Link 12/2020
1	Proteinase-Activated ReceptorsIBA 12/2020
1	Trifluoroacetic Acid (Trifluoroacetate)IBA 12/2020
1	Cannabinoid Receptor AgonistsIBA 01/2020
1	ubrogepantIBA 01/2020
1	lasmiditanIBA 01/2020
1	5-HT1F Serotonin ReceptorIBA 01/2020
1	Biological ProductsIBA 01/2020
1	CannabinoidsIBA 01/2020
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2020
1	Nitroprusside (Sodium Nitroprusside)FDA LinkGeneric 01/2020
1	Nitric Oxide DonorsIBA 01/2020
1	Narcotic Antagonists (Opioid Antagonists)IBA 01/2019
1	isospaglumic acid (NAAGA)IBA 01/2018
1	Non-Narcotic Analgesics (Analgesics, Non Narcotic)IBA 12/2017
1	Mitogen-Activated Protein KinasesIBA 07/2017
1	U 0126 (UO 126)IBA 07/2017
1	Freund's AdjuvantIBA 12/2016
1	Sucrose (Saccharose)IBA 12/2016
1	Diclofenac (SR 38)FDA LinkGeneric 10/2015
1	Clonidine (ST 155)FDA LinkGeneric 05/2015
1	KetorolacIBA 08/2014
1	Naproxen (Naprosyn)FDA LinkGeneric 08/2014
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 08/2014
1	Local AnestheticsIBA 12/2012

Therapy/Procedure

14	Therapeutics 01/2022 - 04/2013
12	Ligation 04/2022 - 06/2012
3	Diffuse Noxious Inhibitory Control 01/2021 - 01/2019
1	Oral Administration 01/2020
1	Anesthesia 12/2019
1	Self Administration (Administration, Self) 04/2013